Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to $1.6 million.

  • Evogene's Receivables - Other fell 3161.02% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3161.02%. This contributed to the annual value of $2.1 million for FY2024, which is 3057.52% down from last year.
  • Evogene's Receivables - Other amounted to $1.6 million in Q3 2025, which was down 3161.02% from $680000.0 recorded in Q2 2025.
  • Evogene's 5-year Receivables - Other high stood at $3.7 million for Q2 2024, and its period low was $651000.0 during Q1 2025.
  • Over the past 5 years, Evogene's median Receivables - Other value was $2.2 million (recorded in 2022), while the average stood at $2.1 million.
  • Per our database at Business Quant, Evogene's Receivables - Other soared by 16046.51% in 2024 and then plummeted by 8160.17% in 2025.
  • Quarter analysis of 5 years shows Evogene's Receivables - Other stood at $2.7 million in 2021, then crashed by 44.1% to $1.5 million in 2022, then soared by 100.61% to $3.0 million in 2023, then tumbled by 30.58% to $2.1 million in 2024, then dropped by 21.8% to $1.6 million in 2025.
  • Its Receivables - Other stands at $1.6 million for Q3 2025, versus $680000.0 for Q2 2025 and $651000.0 for Q1 2025.